Cantor Fitzgerald Forecasts ELDN FY2025 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Eledon Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings of ($1.12) per share for the year. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.63) per share.

Eledon Pharmaceuticals (NASDAQ:ELDN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02).

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Eledon Pharmaceuticals in a research note on Wednesday, November 20th.

Eledon Pharmaceuticals Trading Up 1.0 %

Shares of Eledon Pharmaceuticals stock opened at $4.25 on Wednesday. Eledon Pharmaceuticals has a 52 week low of $1.52 and a 52 week high of $5.54. The stock has a market cap of $253.90 million, a PE ratio of -2.11 and a beta of 0.79. The company’s 50-day moving average price is $4.28 and its two-hundred day moving average price is $3.45.

Hedge Funds Weigh In On Eledon Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP acquired a new position in shares of Eledon Pharmaceuticals in the 2nd quarter valued at $80,000. Renaissance Technologies LLC lifted its stake in Eledon Pharmaceuticals by 57.1% during the second quarter. Renaissance Technologies LLC now owns 136,773 shares of the company’s stock valued at $361,000 after buying an additional 49,704 shares in the last quarter. Armistice Capital LLC boosted its holdings in shares of Eledon Pharmaceuticals by 1.7% in the second quarter. Armistice Capital LLC now owns 2,336,000 shares of the company’s stock worth $6,167,000 after buying an additional 39,000 shares during the period. Nantahala Capital Management LLC purchased a new position in shares of Eledon Pharmaceuticals in the second quarter worth approximately $1,584,000. Finally, Clarity Capital Partners LLC acquired a new stake in shares of Eledon Pharmaceuticals during the third quarter valued at approximately $29,000. 56.77% of the stock is currently owned by institutional investors and hedge funds.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).